Showing 1351-1360 of 1635 results for "".
- Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meetinghttps://modernod.com/news/ocuphire-announces-late-breaking-paper-for-nyxol-for-reversal-of-dilation-indication-at-annual-asrs-meeting/2480950/Ocuphire Pharma today announced six presentations in July at meetings of the American-European Congress of Ophthalmic Surgery (AECOS), American Society of Retina Specialists (ASRS), Ophthalmology Innovation Summit (OIS), and the Octane and National Medical Association (NMA). At ASR
- Formosa Pharmaceuticals and AimMax Therapeutics Announce Topline Results from CPN-301 for the Treatment of Inflammation and Pain After Cataract Surgeryhttps://modernod.com/news/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-topline-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/2480937/Formosa Pharmaceuticals and AimMax Therapeutics reported successful topline results from CPN-301, the first of two pivotal phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a corticosteroid, clobetasol propionate(0.05%), for the treatment of inflamma
- EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of Uveitis Treatment Yutiq in Chinahttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-announce-approval-of-nda-by-chinas-nmpa-for-uveitis-treatment-yutiq/2480925/EyePoint Pharmaceuticals and OcuMension Therapeutics announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chr
- NIH Researchers Discover New Genetic Eye Diseasehttps://modernod.com/news/nih-researchers-discover-new-genetic-eye-disease/2480909/Researchers from the National Eye Institute (NEI) have identified a new disease that affects the macula. Scientists report their findings on the novel macular dystrophy, which is yet to be named, in JAMA Ophthalmology. Macular dystrophies are disorders that usually cause central visual l
- Phase 3 Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implanthttps://modernod.com/news/phase-3-clinical-study-ind-accepted-in-china-for-alimeras-fluocinolone-acetonide-intravitreal-implant/2480901/Alimera Sciences announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for its IND application to begin the phase 3 clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval
- NIH Study Confirms Benefit of Supplements for Slowing AMDhttps://modernod.com/news/nih-study-confirms-benefit-of-supplements-for-slowing-age-related-macular-degeneration-amd/2480894/The Age-Related Eye Disease Studies (AREDS and AREDS2) established that dietary supplements can slow progression of age-related macular degeneration (AMD), according to the Nationa
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- Aldeyra Therapeutics to Present at MOD Live! 2022 Meetinghttps://modernod.com/news/aldeyra-therapeutics-to-present-at-mod-live-2022-meeting/2480843/Aldeyra Therapeutics announced that Kelly Mizer, Aldeyra’s Vice President, Commercial Strategy and Operations, will present at the MOD Live! 2022 meeting, which will take place in Nashville, Tennessee, May 5–7, 2022. MOD Live! 2022 is an interactive educational program
- SAV-IOL Launches Instant Focus EDOF IOL Technologyhttps://modernod.com/news/sav-iol-launches-instant-focus-edof-iol-technology/2480841/Instant Focus is a unique optical technology designed by Swiss IOL maker SAV-IOL (Swiss Advanced Vision). The technology is designed to replace the accommodative function of the eye’s natural lens after cataract surgery, and is manufactured and marketed directly from their he
- Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseaseshttps://modernod.com/news/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases/2480756/Opus Genetics announced a strategic manufacturing services agreement with National Resilience, a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline. Resilience